Celtaxsys, an Atlanta-based pharmaceutical discovery and development company, has restructured its management and operations to focus on development of its lead clinical stage drug candidate, CTX-4430, for treatment of Cystic Fibrosis.
Dr. Michael Hanley has retired as chief executive officer and chairman, and Dr. Brett Premack has stepped down as chief technology officer. Dr. H. Daniel Perez, a member of the Celtaxsys board and former chief executive officer of Berlex Biosciences and Presidio Pharmaceuticals, is serving as chairman.
Ed Philpot, M.D., now is chief medical officer. Philpot has been chair of the medical advisory panel for the CTX-4430 development program for the past year and was formerly chief medical officer at Smith & Nephew and previously executive director of pulmonary disease and immuno-inflammation at GlaxoSmithKline, where he led several late stage clinical development programs.